Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
Launched by AKROS PHARMA INC. · Oct 16, 2009
Trial Information
Current as of May 15, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Have type 2 diabetes;
- • 2. Body mass index (BMI) of ≤ 45.0 kg/m2;
- • 3. Are either untreated with respect to hypoglycemic agents OR are currently being treated with a stable dose of metformin alone.
- Exclusion Criteria:
- • 1. Females who are pregnant or breast-feeding;
- • 2. Known medical history or presence of type 1 diabetes or pancreatitis, acute metabolic diabetic complications, presence of unstable or rapidly progressing retinopathy, nephropathy or neuropathy;
- • 3. Acute coronary syndrome or uncontrolled hypertension;
- • 4. Does not meet all diet or previous/concomitant medication restrictions criteria, as described in the protocol.
About Akros Pharma Inc.
Akros Pharma Inc. is a dedicated clinical research organization focused on advancing innovative therapeutic solutions across various therapeutic areas. With a commitment to improving patient outcomes, Akros Pharma specializes in the development and execution of clinical trials, leveraging cutting-edge technology and a team of experienced professionals. The company emphasizes collaboration with healthcare providers and stakeholders to ensure rigorous adherence to regulatory standards and ethical practices. Through its strategic approach, Akros Pharma aims to accelerate the drug development process while maintaining the highest quality of research and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Jacksonville, Florida, United States
Indianapolis, Indiana, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Miami, Florida, United States
Chicago, Illinois, United States
Charlotte, North Carolina, United States
Houston, Texas, United States
Dallas, Texas, United States
Oklahoma City, Oklahoma, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Cincinnati, Ohio, United States
Virginia Beach, Virginia, United States
Sacramento, California, United States
Walnut Creek, California, United States
Norfolk, Virginia, United States
Bristol, Tennessee, United States
Carrollton, Texas, United States
Greenbrae, California, United States
Marietta, Georgia, United States
Hollywood, Florida, United States
Hialeah, Florida, United States
Deland, Florida, United States
Great Falls, Montana, United States
Marion, Ohio, United States
Sugar Land, Texas, United States
Corpus Christi, Texas, United States
Oxon Hill, Maryland, United States
Lansdale, Pennsylvania, United States
Paramount, California, United States
West Covina, California, United States
New Bedford, Massachusetts, United States
Katy, Texas, United States
Port Orange, Florida, United States
Chandler, Arizona, United States
Morehead City, North Carolina, United States
Tempe, Arizona, United States
Huntington Park, California, United States
Chino, California, United States
Addison, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials